Public Release Summary on the evaluation of the new active fluazaindolizine in the product Salibro Reklemel active Nematicide

This consultation closed on 10 August 2021.
Consultation period: 
13 July 2021 to 10 August 2021

The Australian Pesticides and Veterinary Medicines Authority (APVMA) is considering an application for approval of the new active constituent fluazaindolizine and registration of the product Salibro Reklemel active Nematicide, containing 500 g/L fluazaindolizine, as a suspension concentrate (SC) formulation. The product is intended for the control of root-knot nematodes in cucurbits, fruiting vegetables and root and tuber vegetables.  

We invite comment from 13 July 2021 to 10 August 2021 on whether approval of the active constituent and registration of the product should be granted.

The APVMA is able to consider comments relating to the legislative grounds, including:

  • occupational health and safety
  • public health
  • chemistry and manufacture
  • residues in food
  • environmental safety
  • trade
  • efficacy and target crop safety.

Download the Public Release Summary on the evaluation of Salibro Reklemel active Nematicide.

For more information see page 17, APVMA Gazette No. 14, July 2021.

Please note: Submissions will be published on the APVMA’s website, unless you have asked for the submission to remain confidential (see public submission coversheet).

Please lodge your submission with a public submission coversheet, which provides options for how your submission will be published.

Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.

Please send your written submission and coversheet by email or post to:

Email: enquiries@apvma.gov.au

Post:

Executive Director Registration Management
Australian Pesticides and Veterinary Medicines Authority
GPO Box 3262
Sydney NSW 2001

Your feedback will be submitted to the APVMA anonymously. If you require a response, please contact us.